Although many people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...
In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push, Vertex’s $10 billion purchase of Crinetics, and more.
Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology megablockbuster Humira, CEO Robert Michael can now declare that “we have never been in a ...
AbbVie (ABBV) fell ~4% on Wednesday as BNP Paribas argued that its immunology blockbuster Skyrizi could face competition from Icotyde, a newly approved plaque psoriasis pill developed by Johnson & ...
Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab-rzaa which is already approved ...
What Is Skyrizi, and Why Does It Matter? Skyrizi (risankizumab-rzaa) is a prescription biologic used to treat certain immune-mediated inflammatory conditions. It is now approved by the FDA for ...
Immunocore’s Kimmtrak (tebentafusp-tebn; injection) has been approved for treating unresectable or metastatic uveal melanoma (mUM) in adults who are HLA-A*02:01 positive and have not received previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results